Universität zu Köln

Journal Article

Al-Batran, S-E., Hofheinz, R. D., Schmalenberg, H., Strumberg, D., Goekkurt, E., Angermeier, S., Zander, T., Potenberg, J., Kopp, H-G., Pink, D., Siegler, G. M., Schenk, M., De Vita, F., Maiello, E., Gaiser, T., Sookthai, D., Bankstahl, U. S., Pauligk, C., Goetze, T. O. and Homann, N. (2020). Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma- Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM. Ann. Oncol., 31. S. S901 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Ansen, S., Schultheis, A., Hellmich, M., Leenders, F., Zander, T., Michels, S., Brockmann, M., Stoelben, E., Groen, H., Timens, W., Buettner, R., Thomas, R. K., Perner, S. and Wolf, J. (2014). PD-L1 expression and genotype in Non-Small Cell Lung Cancer (NSCLC). Oncol. Res. Treat., 37. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262

Baltin, C. T., Bludau, M., Kron, F., Zander, T., Hallek, M., Hoelscher, A. H. and Schroeder, W. (2018). Profit center analysis of esophagectomy. Economical analysis of transthoracic esophagectomy depending on postoperative complications. Chirurg, 89 (3). S. 229 - 237. NEW YORK: SPRINGER. ISSN 1433-0385

Goetze, T. O., Al-Batran, S-E., Zander, T., Reichart, A., Lindig, U., Kleiss, M., Mueller, L., Bolling, C., Seufferlein, T., Reichardt, P., Kullmann, F., Eschenburg, H., Schmittel, A., Egger, M., Block, A., Pauligk, C. and Schmalenberg, H. (2017). A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Goetze, T. O., Schmalenberg, H., Pauligk, C., Zander, T., Reichart, A., Lindig, U., Kleiss, M., Mueller, L., Bolling, C., Seufferlein, T., Reichardt, P., Kullmann, F., Eschenburg, H., Schmittel, A., Egger, M., Block, A. and Al-Batran, S. -E. (2017). A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST). Oncol. Res. Treat., 40. S. 209 - 210. BASEL: KARGER. ISSN 2296-5262

Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J. L., Motoyama, S., Lievre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zhang, J., Zhu, L., Lei, M., Kondo, K., Cleary, J. M. and Moehler, M. (2020). Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. Ann. Oncol., 31. S. S1193 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K. -O., Thomas, R., Zander, T., Schultheis, A. M., Buettner, R. and Wolf, J. (2018). Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann. Oncol., 29 (10). S. 2068 - 2076. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Heydt, C., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Fischer, R., Abdulla, D., Nogova, L., Ueckeroth, F., Pauli, B., Schueller, M., Serke, M., Koschel, D., Krueger, S., Grohe, C., Kambartel, K., Sebastian, M., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 219 - 220. BASEL: KARGER. ISSN 2296-5262

Kron, F., Glossmann, J. P., Lotze, M., Barsoum, M., Winters, S., Normolle, D., Boyiadzis, M., Socinski, M., Bernschein, A., Schmidt-Wolf, I., Funke, B., Meyer, M., von Levetzow, C., Leitzke, S., Hellmich, M., Scheid, C., Kreuzer, K. -A., Kostenko, A., Waldschmidt, D., Heukamp, L., Zander, T., Scheffler, M., Hallek, M. and Wolf, J. (2014). A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany. Oncol. Res. Treat., 37. S. 95 - 96. BASEL: KARGER. ISSN 2296-5262

Kron, F., Kostenko, A., Glossmann, J., Hallek, M., Scheffler, M., Zander, T. and Wolf, J. (2016). Economic burden in lung cancer trials: Experience in a Comprehensive Cancer Center in Germany. Oncol. Res. Treat., 39. S. 112 - 113. BASEL: KARGER. ISSN 2296-5262

Kron, F., Kostenko, A., Scheffler, M., Glossmann, J., Fischer, R., Michels, S., Nagoya, L., Hallek, M., Zander, T. and Wolf, J. (2016). Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Oncol. Res. Treat., 39. S. 88 - 89. BASEL: KARGER. ISSN 2296-5262

Kron, F., Kostenko, A., Scheffler, M., Mueller, D., Glossmann, J. -P., Fischer, R., Michels, S., Nogova, L., Hallek, M., Zander, T. and Wolf, J. (2017). Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Lung Cancer, 108. S. 134 - 140. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332

Kron, F., Nadine, K., Kostenko, A., Dohle, I, Mueller, D., Bahlo, J., Bergwelt, M., Eichhorst, B., Hallek, M. and Zander, T. (2016). Profit center analysis of chronic lymphatic leukemia cases: a hospital management perspective. Oncol. Res. Treat., 39. S. 258 - 259. BASEL: KARGER. ISSN 2296-5262

Macherey, S., Preuss, S. F., Doerr, F., Groenke, S., Heldwein, M., Quaas, A., Zander, T. and Hekmat, K. (2014). Surgical therapy of lung metastases from head and neck cancer. HNO, 62 (12). S. 893 - 902. NEW YORK: SPRINGER. ISSN 1433-0458

Marquez, Ma Garcia, Thelen, M., Bauer, E., Wennhold, K., Lehmann, J., Keller, D., Maas, L., Nicolik, M., George, J., Zander, T., Schroeder, W., Mueller, P., Bruns, C., Thomas, R., Gathof, B., Quaas, A., Hillmer, A. M., Peifer, M., von Bergwelt-Baildon, M. and Schloesser, H. A. (2022). HEREDITARY HOMOZYGOSITY AND ALLELIC IMBALANCE OF HLA AS COMMON IMMUNE ESCAPE MECHANISMS IN ESOPHAGEAL ADENOCARCINOMA. J. Immunother. Cancer, 10. S. A38 - 1. LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426

Moehler, M., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lievre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zhang, J., Soleymani, S., Lei, M., Kondo, K., Cleary, J. and Kelly, R. J. (2021). Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577. Ann. Oncol., 32. S. S1045 - 3. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Ozretic, L., Wagner, S., Huebbers, C. U., Gattenloehner, S., Klussmann, J. P., Beutner, D., Zander, T., Buettner, R. and Quaas, A. (2016). FGFR1 amplification and co-overexpression of c-MYC in oropharyngeal squamous cell carcinoma. Oral Oncol., 54. S. E7 - 3. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1879-0593

Pasternack, H., Fassunke, J., Plum, P., Chon, S., Merkelbach-Bruse, S., Bruns, C., Perner, S., Hallek, M., Buttner, R., Zander, T., Quaas, A., Weiss, J. and Alakus, H. (2017). Detection of Somatic Alterations in Circulating Cell-free DNA of Esophageal Carcinoma Patients during Primary Staging is Predictive for Post-surgical Tumor Recurrence. J. Mol. Diagn., 19 (2). S. S37 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Quaas, A., Schloesser, H., Fuchs, H., Zander, T., Arolt, C., Scheel, A. H., Rueschoff, J., Bruns, C., Buettner, R. and Schroeder, W. . Improved Tissue Processing in Esophageal Adenocarcinoma After Ivor Lewis Esophagectomy Allows Histological Analysis of All Surgically Removed Lymph Nodes with Significant Effects on Nodal UICC Stages. Ann. Surg. Oncol.. NEW YORK: SPRINGER. ISSN 1534-4681

Quaas, A., Waldschmidt, D., Alakus, H., Zander, T., Heydt, C., Goeser, T., Daheim, M., Kasper, P., Plum, P., Bruns, C., Brunn, A., Roth, W., Hartmann, N., Bunck, A., Schmidt, M., Goebel, H., Tharun, L., Buettner, R. and Merkelbach-Bruse, S. (2018). Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel. BMC Gastroenterol., 18. LONDON: BIOMED CENTRAL LTD. ISSN 1471-230X

Riedel, R., Kron, A., Michels, S., Fassunke, J., Scheffler, M., Fischer, R., Nogova, L., Abdulla, D., Heydt, C., Ueckeroth, F., Pauli, B., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Sebastian, M., Koschel, D., Kambartel, K-O., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Rubbert-Roth, A., Zander, T., Kneitz, C., Baerwald, C., Wirtz, H. and Witt, C. (2016). Lung cancer and rheumatoid arthritis. An interdisciplinary challenge. Z. Rheumatol., 75 (1). S. 47 - 54. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1435-1250

Scheffler, M., Bos, M., Sos, M., Nogova, L., Gardizi, M., Mattonet, C., Papachristou, I., Kahraman, D., Kobe, C., Lammertsma, A., Boellaard, R., Persigehl, T., Heukamp, L., Buettner, R., Elter, T., Toepelt, K., Engel-Riedel, W., Stoelben, E., Neumaier, B., Dietlein, M., Zander, T. and Wolf, J. (2014). MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Heukamp, L., Koenig, K., Serke, M., Nogova, L., Toepelt, K., Stoelben, E., Engel-Riedel, W., Randerath, W., Kaminsky, B., Panse, J., Zander, T., Buettner, R. and Wolf, J. (2014). Clinical and Molecular Characteristics of Non-Small Cell Lung Cancer Patients Harboring PIK3CA Mutations. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Nogova, L., Papachristou, I., Persigehl, T., Dietlein, F., Zander, T. and Wolf, J. (2014). BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. Oncol. Res. Treat., 37. S. 131 - 132. BASEL: KARGER. ISSN 2296-5262

Schoemmel, M., Loeser, H., Kraemer, M., Wagener-Ryczek, S., Hillmer, A., Bruns, C., Thelen, M., Schroeder, W., Zander, T., Lechner, A., Buettner, R., Schloesser, H., Gebauer, F. and Quaas, A. (2021). Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus. Clin. Transl. Oncol., 23 (8). S. 1601 - 1611. CHAM: SPRINGER INT PUBL AG. ISSN 1699-3055

Ullrich, R. T., Zander, T., Wolf, J. and Hallek, M. (2012). Personalised treatment of lung cancer. Dtsch. Med. Wochenschr., 137 (42). S. 2179 - 2181. STUTTGART: GEORG THIEME VERLAG KG. ISSN 0012-0472

Vella, G., Krebs, S., Funke, B., Glossmann, J. -P., Zander, T., Schmidt-Wolf, I., Hallek, M. and Wolf, J. (2018). Managing Common Organizational Data across Sites in Comprehensive Cancer Centers - Harmonizing Approaches at the University Hospitals of Cologne and Bonn. Oncol. Res. Treat., 41. S. 127 - 129. BASEL: KARGER. ISSN 2296-5262